Presentation is loading. Please wait.

Presentation is loading. Please wait.

A 1 Alosetron 2000 6/26 Elizabeth B. Andrews, Ph.D., M.P.H. Director, Worldwide Epidemiology.

Published byMeagan Stephens Modified over 9 years ago

Similar presentations

Presentation on theme: "A 1 Alosetron 2000 6/26 Elizabeth B. Andrews, Ph.D., M.P.H. Director, Worldwide Epidemiology."— Presentation transcript:

1 A 1 Alosetron 2000 6/26 Elizabeth B. Andrews, Ph.D., M.P.H. Director, Worldwide Epidemiology

2 A 2 Alosetron 2000 6/26 Risk Management Plan

3 A 3 Alosetron 2000 6/26 GW Program of Responsible Product Stewardship Scientific foundation to understand the risks and predictors of serious events Scientific foundation to understand the risks and predictors of serious events Communication program to educate physicians, pharmacists and patients Communication program to educate physicians, pharmacists and patients Program evaluation to determine if and when additional efforts are warranted Program evaluation to determine if and when additional efforts are warranted

4 A 4 Alosetron 2000 6/26 Epidemiologi c Research Communication Program Evaluation Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

5 A 5 Alosetron 2000 6/26 Epidemiologi c Research Communication Program Evaluation Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

6 A 6 Alosetron 2000 6/26 Epidemiologi c Research Program Evaluation Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Communication Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

7 A 7 Alosetron 2000 6/26 Epidemiologi c Research Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Program Evaluation Communication Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

8 A 8 Alosetron 2000 6/26 Epidemiologi c Research Communication Program Evaluation Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

9 A 9 Alosetron 2000 6/26 Recent launchRecent launch Interest highInterest high Many options consideredMany options considered Strategy consistent with the evidenceStrategy consistent with the evidence –Appropriate patients –Early recognition Risk Management Strategy Opportunity

10 A 10 Alosetron 2000 6/26 Risk Definition Epidemiology Program

11 A 11 Alosetron 2000 6/26 Contributions of Epidemiology Studies vs Clinical Trials Large numbers of patientsLarge numbers of patients Real world experienceReal world experience –more heterogeneous patients –treatment and compliance less controlled Estimate infrequent/rare eventsEstimate infrequent/rare events Explore risk factors for eventsExplore risk factors for events Trade depth (trial) for breadth (epidemiology)Trade depth (trial) for breadth (epidemiology)

12 A 12 Alosetron 2000 6/26 Program of Epidemiology Research: Questions Addressed Frequency of complications of constipation in patients treated with Lotronex in actual practiceFrequency of complications of constipation in patients treated with Lotronex in actual practice Frequency of ischemic colitis in patients treated with Lotronex compared with other populations – persons with IBS, persons who consult GI specialists, general populationFrequency of ischemic colitis in patients treated with Lotronex compared with other populations – persons with IBS, persons who consult GI specialists, general population Potential risk factorsPotential risk factors

13 A 13 Alosetron 2000 6/26 General Study Designs Observational cohort studies to define incidence of complications of constipation and ischemic colitisObservational cohort studies to define incidence of complications of constipation and ischemic colitis Nested case-control studies to evaluate risk factorsNested case-control studies to evaluate risk factors

14 A 14 Alosetron 2000 6/26 Methodologic Issues ChallengesChallenges –Spectrum of disease –ICD-9 code is non-specific ApproachesApproaches –Broad capture of ICD-9 codes –Development of computer algorithms –Validation through chart review

15 A 15 Alosetron 2000 6/26 Epidemiology Commitments GW and FDA agreed to a Phase IV observational cohort studyGW and FDA agreed to a Phase IV observational cohort study 10,000 patients treated with Lotronex10,000 patients treated with Lotronex GW is modifying the study to include complications of constipationGW is modifying the study to include complications of constipation

16 A 16 Alosetron 2000 6/26 Observational Cohort Study of Safety in Patients Receiving Lotronex Objectives 1.Incidence and risk factors for complications of constipation in patients receiving Lotronex 2.Incidence and risk factors for ischemic colitis in patients receiving Lotronex 3.Incidence of these events in the general population and in patients with IBS not receiving Lotronex

17 A 17 Alosetron 2000 6/26Datasource United HealthCare (UHC) Research DatabaseUnited HealthCare (UHC) Research Database Second largest health care company in the United States: >300,000 physicians, >14 million membersSecond largest health care company in the United States: >300,000 physicians, >14 million members UHC Research Database subset comprised of 7 million members since 1990 with medical and prescription coverageUHC Research Database subset comprised of 7 million members since 1990 with medical and prescription coverage Observational Cohort Study of Safety in Patients Receiving Lotronex

18 A 18 Alosetron 2000 6/26 Study Conduct: Phase I Development of algorithms using computerized claims to identify patients with diagnoses under studyPhase I Development of algorithms using computerized claims to identify patients with diagnoses under study Phase II Incidence of events in patients receiving LotronexPhase II Incidence of events in patients receiving Lotronex Phase III Further characterize events in patients with IBS, and in general populationPhase III Further characterize events in patients with IBS, and in general population Observational Cohort Study of Safety in Patients Receiving Lotronex

19 A 19 Alosetron 2000 6/26 Utilization Study Question: Descriptive study of utilization patterns over time in United HealthCareQuestion: Descriptive study of utilization patterns over time in United HealthCare Population: All persons receiving a prescription for LotronexPopulation: All persons receiving a prescription for Lotronex Analysis: Descriptive evaluation of users by :Analysis: Descriptive evaluation of users by : –Age –Gender –History of constipation –History of IBS-related visits and prescriptions

20 A 20 Alosetron 2000 6/26 This study is also part of Program EvaluationThis study is also part of Program Evaluation Systematic evaluationSystematic evaluation First review December 2000, quarterly thereafterFirst review December 2000, quarterly thereafter Utilization Study

21 A 21 Alosetron 2000 6/26 Epidemiology: Program of Research StudyPopulationTimeline Phase IV Study of Safety UHC Research First interim in 10,000 patients Database report treated with Lotronex 7 million members December 2000 Disease frequency/ GPRD (UK) Complete risk factors in 6 million patients December 2000 general population and patients with IBS

22 A 22 Alosetron 2000 6/26 Epidemiology: Program of Research (continued) StudyPopulationTimeline Disease frequency TN Medicaid Complete Fall and risk factors 1.4 million patients 2002 Disease frequency Mayo Clinic & Complete Fall and risk factors Foundation 2002 Residents of Olmstead County Case control study Patients in GW Initiate Summer in GW Clinical Trials Clinical Trials 2000

23 A 23 Alosetron 2000 6/26 Risk Definition Clinical Studies

24 A 24 Alosetron 2000 6/26 Program of Clinical Studies Study on constipation managementStudy on constipation management –Laxatives –Interruption of therapy –Dose reduction Studies for other indications/populationsStudies for other indications/populations –Male IBS –Functional Dyspepsia

25 A 25 Alosetron 2000 6/26 Risk Definition Mechanistic Studies

26 A 26 Alosetron 2000 6/26 Mechanistic Studies Phase IV commitmentPhase IV commitment –Cultured endothelial cell integrity Mesenteric blood flow in humans with PET scanningMesenteric blood flow in humans with PET scanning Coagulation factorsCoagulation factors

27 A 27 Alosetron 2000 6/26 Epidemiologi c Research Communication Program Evaluation Systematic Evaluation Risk Definition Mechanisti c Studies Clinical Studies Risk Management Strategy An Integrated Approach Appropriate Use ProgramAppropriate Use Program Healthcare PractitionersHealthcare Practitioners PharmacistsPharmacists PatientsPatients Testing Comprehension of Communication VehiclesTesting Comprehension of Communication Vehicles Tracking Awareness and Source of KnowledgeTracking Awareness and Source of Knowledge Lotronex Utilization StudyLotronex Utilization Study Ongoing pharmacovigilanceOngoing pharmacovigilance

Download ppt "A 1 Alosetron 2000 6/26 Elizabeth B. Andrews, Ph.D., M.P.H. Director, Worldwide Epidemiology."

Similar presentations

What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,

What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,
5th Annual PBM Pharmacy Informatics Conference

5th Annual PBM Pharmacy Informatics Conference
Early stages of research programmes: pilot and feasibility studies From Scoping to Activity Rehabilitation Conference A Byrne.

Early stages of research programmes: pilot and feasibility studies From Scoping to Activity Rehabilitation Conference A Byrne.
AnCompany.... Monitoring New Drugs for Safety in Insurance Claims Alexander M. Walker Sr VP Epidemiology I3 Magnifi.

AnCompany.... Monitoring New Drugs for Safety in Insurance Claims Alexander M. Walker Sr VP Epidemiology I3 Magnifi.
Disease State Management The Pharmacist’s Role

Disease State Management The Pharmacist’s Role
“ Linking Blood Pressure and Cardiovascular Health” Welcome We invite you to explore what a membership in the American Society of Hypertension, Inc. (ASH)

“ Linking Blood Pressure and Cardiovascular Health” Welcome We invite you to explore what a membership in the American Society of Hypertension, Inc. (ASH)
1 February 9, 2007 Indigent Care Collaboration HIE Supports Community Collaboration February 9, 2007 Ann Kitchen  Executive Director Indigent Care Collaboration.

1 February 9, 2007 Indigent Care Collaboration HIE Supports Community Collaboration February 9, 2007 Ann Kitchen  Executive Director Indigent Care Collaboration.
SUTENT  (sunitinib malate) capsules Access Slide Kit.

SUTENT  (sunitinib malate) capsules Access Slide Kit.
Area 4 SHARP Face-to-Face Conference Phenotyping Team – Centerphase Project Assessing the Value of Phenotyping Algorithms June 30, 2011.

Area 4 SHARP Face-to-Face Conference Phenotyping Team – Centerphase Project Assessing the Value of Phenotyping Algorithms June 30, 2011.
Drug Utilization Review (DUR)

Drug Utilization Review (DUR)
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.

2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Brian L. Strom, M.D., M.P.H. Chair and Professor, Department of Biostatistics and Epidemiology Director, Center for Clinical Epidemiology and Biostatistics.

Brian L. Strom, M.D., M.P.H. Chair and Professor, Department of Biostatistics and Epidemiology Director, Center for Clinical Epidemiology and Biostatistics.
Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.

Health Line of Business Revised Health Domains January 26, 2005 Outcomes / Domains have been revised.
Documentation for Acute Care

Documentation for Acute Care
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.

Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.

Prescription Opioid Use and Opioid-Related Overdose Death — TN, 2009–2010 Jane A.G. Baumblatt, MD Centers for Disease Control and Prevention Epidemic Intelligence.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,

As noted by Gary H. Lyman (JCO, 2012) “CER is an important framework for systematically identifying and summarizing the totality of evidence on the effectiveness,
Norfolk Services Board Integrated Care Clinic “I-CARE” Norfolk Community Services Board Integrated Care Clinic “I-CARE” Cohort IV Learning Community Region.

Norfolk Services Board Integrated Care Clinic “I-CARE” Norfolk Community Services Board Integrated Care Clinic “I-CARE” Cohort IV Learning Community Region.

Similar presentations

Ads by Google